A Randomized, Open-label, Single-period, Parallel-group Study in Healthy Subjects to Determine the Effects of Dissolution Profile on the Pharmacokinetics (Via Both Venous and Peripheral Micro-samples) of Single Oral 300 mg Doses of Tafenoquine (SB-252263) Tablets + 30 mg Tafenoquine Stable Isotope Labelled (SIL) Solution
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Tafenoquine (Primary) ; Tafenoquine (Primary)
- Indications Malaria
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.